Navigation Links
Tengion Appoints A. Brian Davis Chief Financial Officer

EAST NORRITON, Pa., Aug. 2 /PRNewswire-FirstCall/ -- Tengion Inc. (Nasdaq: TNGN) today announced that it has appointed A. Brian Davis to the position of Chief Financial Officer.  Mr. Davis comes to Tengion after 15 years with Neose Technologies, Inc., a biopharmaceutical company using enzymatic technologies to develop improved protein therapeutics. At its peak, Neose employed 200 individuals, including cGMP production, development and research personnel at three sites. 

"Brian's demonstrated excellence as a public biotech company CFO, his strong accounting and finance background, and his experience supporting financial evaluation of business development transactions will be valuable to Tengion as we continue to advance the company and our product candidates," stated Steven Nichtberger, M.D., President and Chief Executive Officer of Tengion.

Mr. Davis advanced from Controller to SVP and CFO at Neose, and brings highly relevant experience to Tengion including raising over $300 million in public and private equity and debt, financial evaluation of business development transactions, treasury and cash management, SEC reporting, Sarbanes-Oxley compliance, and investor relations.  Mr. Davis holds a BS in Accounting from Trenton State College and an MBA from the Wharton School of the University of Pennsylvania. He is a Certified Public Accountant.

Linda Hearne, Tengion's Vice President, Finance, will be stepping down from her role in order to relocate with her family overseas.  "During her nearly six years with Tengion, Linda has played a defining role in the development of our finance function and was instrumental in our becoming a public company earlier this year.  We wish Linda and her family all the best in their new life abroad and we are grateful that she will remain with Tengion in the coming weeks to ensure a smooth transition," said Dr. Nichtberger.  

About Tengion

Tengion, a clinical-stage biotechnology company, has pioneered the Organ Regeneration Platform that enables us to create proprietary product candidates that are intended to harness the intrinsic regenerative pathways of the body to produce a range of native-like organs and tissues. Our product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. Tengion commenced a Phase I clinical trial in the first half of 2010 for its lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. Tengion has also applied its technology in two Phase II clinical trials for Tengion's Neo-Bladder Augment™ for the treatment of neurogenic bladder and is in pre-clinical development of its Neo-Kidney Augment™. Tengion has worldwide rights to its product candidates.

SOURCE Tengion Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Tengion Presents New Data Supporting its Organ Regeneration Platform™ at 8th Annual Meeting of the International Society for Stem Cell Research
2. Tengion Presents New Data Supporting Key Urologic and Kidney Programs at 16th Annual Meeting of the International Society for Cellular Therapy
3. Tengion to Present at the Piper Jaffray 20th Annual Healthcare Conference
4. Tengion Announces Second Closing of Series C Financing
5. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
6. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
7. CMP Therapeutics Appoints Dr Neill Moray Mackenzie as CEO
8. Adeona Appoints Julie A. Caudill, B.B.A., Vice President of Finance and Corporate Controller
9. Chimerix Appoints Two New Vice Presidents to Clinical Management Team
10. SemBioSys Appoints President of US and International Operations and Announces the Appointments of Three Vice Presidents
11. Biostar Pharmaceuticals, Inc. Appoints New Chief Financial Officer
Post Your Comments:
(Date:6/24/2016)... NC (PRWEB) , ... June 24, 2016 , ... Researchers ... the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings are ... to read it now. , Diagnostic biomarkers are signposts in the blood, lung ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one of ... their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has been ... Target to its list of well-respected retailers. This list includes such fine stores ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
Breaking Biology Technology:
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
(Date:6/2/2016)... , June 2, 2016 The ... has awarded the 44 million US Dollar project, for ... Embossed Vehicle Plates including Personalization, Enrolment, and IT Infrastructure ... leader in the production and implementation of Identity Management Solutions. ... January, however Decatur was selected for ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):